
Annexon Inc
ANNXHealthcare|Biotechnology|USA
$5.79
-0.14 (-2.36%)
Tangible Book
$1.26
Earnings Power
$0.88
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
44.35,
192.46,
388.51,
861.54
],
"ebit_estimate": [
-200.64,
-192.4,
-18.97,
248.05,
654.75
],
"ebitda_estimate": [
-201.99,
-209.42,
-198.15,
null,
null
],
"net_income_estimate": [
-188.52,
-176.71,
-5.7,
303.4,
663.4
],
"per_share_eps_estimate": [
-0.94,
-0.78,
0.1,
0.96,
2.35
],
"eps_nri_estimate": [
-0.96,
-0.82,
-0.02,
1.11,
2.8
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-189.9,
-185.85,
2.55,
334.65,
767.17
],
"operating_cash_flow_per_share_estimate": [
-0.86,
-0.47,
null,
null,
null
],
"roa_estimate": [
-78.4,
-140.4,
null,
null,
null
],
"roe_estimate": [
-112.75,
-226.5,
null,
null,
null
],
"gross_margin_estimate": [
87.5,
85,
84,
88.5,
92
],
"operating_cash_flow_estimate": [
-166.04,
-91.27,
null,
null,
null
],
"pettm_estimate": [
0,
0,
57.95,
6.04,
2.47
],
"long_term_growth_rate_mean": 70.56,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": 70.56,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 52.02,
"future_ebitda_estimate_growth": 1.96,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 66.27,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
null,
null,
null,
1.73,
1.8,
2.89,
7.06
],
"ebit_estimate": [
-49.74,
-52.37,
-55.18,
-53.03,
-60.8,
-66.45,
-71.13
],
"ebitda_estimate": [
-49.07,
-52.3,
-55.89,
null,
null,
null,
null
],
"net_income_estimate": [
-45.79,
-48.51,
-50.28,
-50,
-57.96,
-64.14,
-69.03
],
"per_share_eps_estimate": [
-0.23,
-0.24,
-0.23,
-0.23,
-0.26,
-0.28,
-0.2
],
"eps_nri_estimate": [
-0.24,
-0.25,
-0.25,
-0.23,
-0.26,
-0.28,
-0.2
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-45.96,
-48.35,
-50.35,
-50,
-57.96,
-64.14,
-69.03
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": 70.56,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": null,
"future_eps_nri_estimate_growth": 70.56,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": 52.02,
"future_ebitda_estimate_growth": 1.96,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": 66.27,
"future_pretax_income_estimate_growth": null,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": null
}